Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
100Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.84B | $1.84M | $0.14 |
| 2024 | $1.90B | $111.19M | $7.81 |
| 2023 | $1.94B | $289.24M | $21.03 |
| 2022 | $1.62B | $-34.29M | $-2.53 |
| 2021 | $986.85M | $-177.39M | $-13.32 |
Social Signal Score
Earnings
Wed, Oct 28(in 2 months)
Consensus estimate $1.51 per share
Typical surprise -43.4% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 28$-0.38 vs $0.43miss
- Wed, Apr 29$0.98 vs $1.73miss
- Wed, Feb 11$1.37 vs $1.11beat
- Wed, Oct 22$-0.37 vs $1.20miss
- Tue, Jul 29$0.77 vs $-0.02beat
- Wed, Apr 23$1.53 vs $1.57miss
Estimates and results for PDS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.20
- Implied price
- $3.65
- Return from $84.63
- -46.7% a year
To earn 15.0% a year on these assumptions you'd need to buy at $1.82 — -97.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -55.4% | -53.3% | -51.6% | -50.1% | -48.7% |
| 3.0% | -53.1% | -51.0% | -49.1% | -47.5% | -46.1% |
| 8.0% | -50.8% | -48.6% | -46.7% | -45.0% | -43.5% |
| 13.0% | -48.5% | -46.2% | -44.2% | -42.4% | -40.9% |
| 18.0% | -46.3% | -43.8% | -41.7% | -39.9% | -38.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (3)
- Newsglobenewswire.com·2d ago·Neutral
PDS Biotech Reports Second Quarter 2026 Financial Results PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a clinical-stage biotechnology company focused on developing targeted immunotherapies for cancer, today provided a business and clinical programs update and reported financial results for the quarter ended June 30, 2026.
View source ↗ - Newsbenzinga.com·4d ago·Negative
PDS Biotechnology Stock Crashes, Strategic Refocus Pivots to Metastatic Colorectal Cancer Program PDS Biotechnology Corporation (NASDAQ:PDSB) shares have fallen by about 67% on Tuesday as the company announced a strategic refocus on its PDS0301 program for metastatic colorectal cancer.
View source ↗ - Newszacks.com·5d ago·Neutral
Will Lower PDS Margin Affect Aveanna Healthcare's Q2 Earnings? AVAH's Q2 revenues are expected to rise 9.8%, but lower PDS margins and higher costs may weigh on earnings.
View source ↗